Bayer (OTCPK:BAYR.Y) Update / briefing Transcript

Summary of the Oceanic Stroke Phase III Trial Conference Call Company and Industry Overview - Company: Bayer - Industry: Pharmaceutical, specifically focusing on stroke prevention and treatment Key Points and Arguments Unmet Medical Need in Stroke Prevention - Over 100 million stroke survivors globally, with 12 million new cases annually - Stroke is the third leading cause of death and the second leading cause of disability - 20% of stroke survivors will experience a second stroke within five years, with 10% within one year - Recurrent strokes are more severe and can lead to increased disability and dementia [3][4] Asundexian Overview - Asundexian is the first oral, once-daily Factor XIa inhibitor that completed a Phase III trial for secondary stroke prevention - The trial was designed to represent a broad stroke population and align with current clinical practices [5][6] - Bayer aims for Asundexian to become the new standard of care in secondary stroke prevention, with blockbuster potential [6] Trial Design and Results - The OCEANIC-STROKE trial was a placebo-controlled, double-blinded study involving 12,327 participants across 702 sites in 37 countries [10][15] - Primary efficacy endpoint: time to first occurrence of ischemic stroke; primary safety endpoint: time to first occurrence of major bleeding [10][11] - Asundexian demonstrated a 26% reduction in the hazard of ischemic stroke compared to placebo [21] - Significant reductions in all stroke types and cardiovascular events were observed [22] Safety Profile - No significant increase in major bleeding or other safety endpoints compared to placebo [23] - The trial showed a consistent safety profile across various subgroups, including those with different stroke subtypes [29][30] Economic Impact and Market Potential - The global financial impact of stroke is nearing $900 billion, projected to exceed $1 trillion by 2030 [33] - Preventing recurrent strokes could alleviate economic burdens and improve productivity among stroke survivors [34] - Bayer is in discussions with health authorities to expedite the approval process for Asundexian [36] Future Considerations - Bayer is exploring additional indications for Asundexian, including its potential use in patients with atrial fibrillation [52] - The company is focused on understanding the total economic impact of stroke to inform pricing strategies for Asundexian [42] Other Important Content - The trial included a diverse population, with significant representation of various demographics, although there were challenges in recruiting female participants [17][18] - The study's design and results are expected to influence future treatment guidelines and practices in stroke prevention [36] - Bayer's commitment to making Asundexian available quickly reflects the urgency of addressing the unmet needs in stroke prevention [36]